How Insilico Medicine’s ISM8969 could unlock a new class of neuroinflammatory drugs
Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.
Alcresta’s RELiZORB shows BMI and weight gains in pediatric tube-fed patients
See how RELiZORB improved weight and BMI z-scores in tube-fed children aged 1–5 in new real-world data. Explore what this means for pediatric care today.
Why FDA’s clearance of ACON’s Flowflex Plus test marks a turning point in home diagnostics
FDA clears Flowflex Plus 4-in-1 test for RSV, flu, and COVID in infants and adults. Find out what this means for diagnostics, families, and industry players.
Can ELEVIDYS meet its promise? Sarepta’s pivotal Duchenne gene therapy trial nears major milestone
Sarepta’s EMBARK 3-year readout could clarify ELEVIDYS’ long-term role in Duchenne care. Find out what’s at stake in this pivotal gene therapy trial.
JAMA validates nalbuphine ER’s efficacy in IPF chronic cough as Trevi eyes next steps
Trevi’s IPF cough trial results for nalbuphine ER get published in JAMA. Find out what this means for future approvals and respiratory drug development.
Is Myriad setting a new performance and pricing benchmark in bioscaffold trauma use?
Can Aroa’s bioscaffold platform reshape trauma care economics? See what Myriad’s MASTRR data means for hospitals, surgeons, and reimbursement.
Medtronic expands Affera platform with Sphere-360 catheter CE Mark and IDE trial kickoff
Medtronic’s Sphere-360 catheter earns CE Mark and begins U.S. IDE trial. Find out what this means for the future of pulsed field ablation.
RED-C setback for Bausch Health: What this failed Phase 3 trial reveals about cirrhosis care gaps
Bausch’s RED-C trial failed to meet endpoints in hepatic encephalopathy prevention. Find out what this means for rifaximin SSD’s future and the field.
Nalu Medical’s wearable-powered PNS shows strong 24-month durability in COMFORT RCT
Nalu’s PNS system shows 85% responder rate at 24 months. Find out what this long-term data means for neuromodulation’s future.
Can Agilent’s new slide scanner system shift digital pathology from pilot to mainstream in Europe?
Agilent’s new S540MD slide scanner targets scale and AI integration in European pathology labs. Find out what this means for digitisation strategy.